FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Breckenridge Pharmaceutical Duloxetine Delayed-Release Capsules Recall

Duloxetine Delayed-Release Capsules, USP, 60mg, 90-count bottle, Rx Only, Mfr

Breckenridge Pharmaceutical, Inc · Berlin, CT

Risk level
Class II
Reported by FDA
Jun 26, 2024
Recall ID
D-0562-2024
Check your lot numberHow we source this data

Summary

Breckenridge Pharmaceutical recalled Duloxetine Delayed-Release Capsules starting May 17, 2024. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0562-2024 on Jun 26, 2024. Reason: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. Status: Terminated.

Why it was recalled

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Product description

Duloxetine Delayed-Release Capsules, USP, 60mg, 90-count bottle, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-748-90

Lot numbers, UPCs & expiration codes

Lot #: 230035C, Exp. date 11/30/2025; 230101C, Exp. date 12/31/2025

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0562-2024
Classification
Class II
Status
Terminated
Recall initiated
May 17, 2024
FDA report date
Jun 26, 2024
Quantity
165,678, 90-count bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Breckenridge Pharmaceutical, Inc

Original FDA data

Every field from FDA enforcement report D-0562-2024, exactly as published.

Show all FDA fields
City
Berlin
State
CT
Status
Terminated
Country
United States
Event ID
94611
Address
15 Massirio Dr Ste 201
Code information
Lot #: 230035C, Exp. date 11/30/2025; 230101C, Exp. date 12/31/2025
Postal code
06037-2352
Report date
Jun 26, 2024
Product type
Drugs
Recall number
D-0562-2024
Classification
Class II
Recalling firm
Breckenridge Pharmaceutical, Inc
Product quantity
165,678, 90-count bottles
Termination date
Apr 7, 2026
Reason for recall
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Voluntary / mandated
Voluntary: Firm initiated
Product description
Duloxetine Delayed-Release Capsules, USP, 60mg, 90-count bottle, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-748-90
Distribution pattern
Nationwide in the USA
Recall initiation date
May 17, 2024
Initial firm notification
Letter
Center classification date
Jun 20, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0562-2024, published Jun 26, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls